ASCO 2023 | DESTINY-CRC02: antibody-drug conjugates in colorectal cancer

Jennifer Rachel Eads, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the absence of antibody-drug conjugates (ADCs) indicated for colorectal cancer. Whilst multiple trials have negative results, findings from the Phase II DESTINY-CRC02 trial (NCT04744831) of trastuzumab deruxtecan (T-DXd) in patients with HER2-overexpressing colorectal cancer (CRC) have been promising. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.